GFAP and Mental deterioration: By identifying patients with elevated GFAP or reduced Aβ42/40 ratios, clinicians may better stratify vascular risk, monitor disease progression, and tailor interventions targeting neuroinflammation or amyloid clearance to slow cognitive decline.